Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

Eli Lilly and insitro said the deals offers a “new paradigm” for collaborations between major pharmaceutical companies and smaller biotechs.

Reporting in Nature, Kumar and colleagues have now developed a method to target small-interfering RNA (siRNA) to the CNS, providing a safe and non-invasive approach for the delivery of this new ...

Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo Programs to focus on silencing hard-to-drug targets of high therapeutic ...

Sirna kakuu galuu Pirezidaant Tiraamp Wiixata darbe gaggeeffame irratti paastaroonni Afrikaa lama argamanii turan. Dawwaannaan Paastar Wiiliyaam Kumuuyi fi Paastar Naatinaa'el Baasey kun walitti ...

In SNALPs, the backbone-modified siRNA is encapsulated within a closed shell of a cationic-zwitterionic lipid bilayer, furnished with an outer PEG shield (Figure 2A). The lipid bilayer contains a ...

SIL-204 administered in an extended release formulation reduced tumor growth by ~50% after 30 days, with ~50% of tumors showing complete necrosis, in human pancreatic tumors harboring a G12D mutation ...

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover ...

Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the U.S. Food and Drug Administration (FDA) and Health Canada have cleared the Investigational New Drug ...